Disclaimers

Xeomin ® (Incobotulinumtoxin A) 50, 100 Units is a Prescription Medicine. Indications: In adults, for

the treatment of cervical dystonia; blepharospasm; spasticity of the upper limb; upper facial lines:

glabellar frown lines, lateral periorbital lines (crow’s feet), horizontal forehead lines. Xeomin has

both risks and benefits, consult your doctor if Xeomin is right for you. Further information on the

risks and benefits of Xeomin can be found in the Consumer Medicine Information (CMI) available

from www.medsafe.govt.nz or by calling 0800 822 310. Use strictly as directed. If symptoms

continue or you have side effects, see your doctor, pharmacist or health care professional. Common

side effects include: Headaches; nausea; tenderness, swelling, redness, numbness or bruising of the

skin; dry eye; heavy feeling of eyelid/eyebrow/forehead; face/brow not symmetrical, dropping

eyelids/eyebrows. Serious side effects are rare and include allergic reactions. Xeomin is an unfunded

medicine, prescription charge will apply. Normal doctor charges will still apply.

Copyright © 2023. Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL) 58 Richard Pearse

Drive, Mangere, Auckland 2022. All rights reserved. Xeomin® and Merz Aesthetics are registered

trademarks of Merz Pharma GMbH & Co. KGaA.

For information about how Merz handles personal data, please see Merz General Data Protection

Information Notice at www.merz.com/fin

Teosyal®TEOSYAL RHA® 1, TEOSYAL RHA® 2, TEOSYAL RHA® 3, TEOSYAL RHA® 4, TEOSYAL® PURESENSE REDENSITY 1, TEOSYAL® PURESENSE REDENSITY 2, TEOSYAL PURESENSE KISS ®, TEOSYAL® PURESENSE GLOBAL ACTION, TEOSYAL® PURESENSE  DEEP LINES, TEOSYAL® PURESENSE ULTIMATE and TEOSYAL® PURESENSE ULTRA DEEP are trademark of the firm TEOXANE SA. These products are gel that contains hyaluronic acid, and 0.3% by weight of lidocaine hydrochloride (local anesthetic can induce a positive reaction  to anti-doping tests). In the case of known hypersensitivity to lidocaine and/or amide local anaesthetic agents, we recommend not use lidocaine-containing products and please refer to products without lidocaine. They are class III medical device and are regulated  health product bearing the CE marking (CE2797) under this regulation.
Local manifestations: inflammatory reactions (erythema, oedema, pain at the point of injection), haematomas, itching, temporary loss of sensitivity around the injected area, dyschromia, abscesses, indurations, nodules (possibly granulomas).
General manifestations: immediate hypersensitivity up to anaphylactic shock, migration of the implant.
Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment or blindness, skin necrosis and stroke.
Please consult your physician or pharmacist for more information.
Please refer to instructions for use. The product availability depends on registration, please contact your local distributor. Please inform the manufacturer TEOXANE of any side effects or any claim as soon as possible to the following address:
Trinity Sax|Business Manager NZ
M :+64 2 7252 6841
Teoxane ANZ PTY LTD
9 Cleg Street Artarmon NSW
Australia